A MULTICENTER, RANDOMIZED, CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF APREMILAST IN EARLY PSORIATIC ARTHRITIS PATIENTS WITH OLIGOARTHRITIS AND MODERATE DISEASE ACTIVITY: APTITUDE (APremilasT In paTients With oligoarticUlar Psoriatic Arthritis DiseasE
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms APTITUDE; FOREMOST
- Sponsors Celgene Corporation
- 18 Dec 2018 Planned End Date changed from 31 Mar 2021 to 29 Jan 2021.
- 18 Dec 2018 Status changed from not yet recruiting to recruiting.
- 27 Nov 2018 New trial record